黑色素瘤
癌症研究
下调和上调
PD-L1
外显子组测序
突变
生物
免疫检查点
RAC1
突变体
分子生物学
免疫系统
信号转导
基因
细胞生物学
遗传学
免疫疗法
作者
Ha Linh Vu,Sheera R. Rosenbaum,Timothy J. Purwin,Michael A. Davies,Andrew E. Aplin
摘要
Summary Whole exome sequencing of cutaneous melanoma has led to the detection of P29 mutations in RAC 1 in 5–9% of samples, but the role of RAC 1 P29 mutations in melanoma biology remains unclear. Using reverse phase protein array analysis to examine the changes in protein/phospho‐protein expression, we identified cyclin B1, PD ‐L1, Ets‐1, and Syk as being selectively upregulated with RAC 1 P29S expression and downregulated with RAC 1 P29S depletion. Using the melanoma patient samples in TCGA , we found PD ‐L1 expression to be significantly increased in RAC 1 P29S patients compared to RAC 1 WT as well as other RAC 1 mutants. The finding that PD ‐L1 is upregulated suggests that oncogenic RAC 1 P29S may promote suppression of the antitumor immune response. This is a new insight into the biological function of RAC 1 P29S mutations with potential clinical implications as PD ‐L1 is a candidate biomarker for increased benefit from treatment with anti‐ PD 1 or anti‐ PD ‐L1 antibodies.
科研通智能强力驱动
Strongly Powered by AbleSci AI